StocksMedium•19 October 2026•
1 min read
Veradermics Reports Positive Phase 3 Results for Hair Loss Treatment
Key Facts
1Veradermics announced positive topline results from Part A of its Phase 3 clinical trial evaluating VDPHL01 for male pattern hair loss.
Veradermics announced positive topline results from Part A of its Phase 3 clinical trial evaluating VDPHL01 for male pattern hair loss. The company stated in a Business Wire release that its proprietary extended-release oral minoxidil formulation achieved robust hair growth in the trial, which involved more than 500 male participants.
The company is seeking registration-directed data to support the clinical efficacy of its late-stage biopharmaceutical candidate. MANE closed at $108.82 on October 16, 2026, with the stock trading between a low of $106.51 and a high of $114.25 during that session.